DE69626642D1 - Cetp zur erhöhung des hdl-cholesterol-gehalts - Google Patents

Cetp zur erhöhung des hdl-cholesterol-gehalts

Info

Publication number
DE69626642D1
DE69626642D1 DE69626642T DE69626642T DE69626642D1 DE 69626642 D1 DE69626642 D1 DE 69626642D1 DE 69626642 T DE69626642 T DE 69626642T DE 69626642 T DE69626642 T DE 69626642T DE 69626642 D1 DE69626642 D1 DE 69626642D1
Authority
DE
Germany
Prior art keywords
cetp
hdl cholesterol
increasing
cholesterol content
stimulating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69626642T
Other languages
English (en)
Other versions
DE69626642T2 (de
Inventor
Y Kwoh
W Brostoff
J Carlo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celldex Therapeutics Inc
Original Assignee
Avant Immunotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avant Immunotherapeutics Inc filed Critical Avant Immunotherapeutics Inc
Publication of DE69626642D1 publication Critical patent/DE69626642D1/de
Application granted granted Critical
Publication of DE69626642T2 publication Critical patent/DE69626642T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Ink Jet Recording Methods And Recording Media Thereof (AREA)
  • Color Television Image Signal Generators (AREA)
  • Materials For Photolithography (AREA)
DE69626642T 1995-06-06 1996-06-05 Cetp zur erhöhung des hdl-cholesterol-gehalts Expired - Fee Related DE69626642T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48245495A 1995-06-06 1995-06-06
PCT/US1996/009143 WO1996039168A1 (en) 1995-06-06 1996-06-05 Method for increasing hdl cholesterol level

Publications (2)

Publication Number Publication Date
DE69626642D1 true DE69626642D1 (de) 2003-04-17
DE69626642T2 DE69626642T2 (de) 2004-01-29

Family

ID=23916145

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69626642T Expired - Fee Related DE69626642T2 (de) 1995-06-06 1996-06-05 Cetp zur erhöhung des hdl-cholesterol-gehalts

Country Status (9)

Country Link
US (1) US7074407B1 (de)
EP (1) EP0831881B1 (de)
JP (1) JP3910635B2 (de)
AT (1) ATE234109T1 (de)
CA (1) CA2223177A1 (de)
DE (1) DE69626642T2 (de)
DK (1) DK0831881T3 (de)
ES (1) ES2190470T3 (de)
WO (1) WO1996039168A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
CA2223177A1 (en) 1995-06-06 1996-12-12 The Immune Response Corporation Method for increasing hdl cholesterol level
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
US6846808B1 (en) 1996-05-01 2005-01-25 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
JP2001520204A (ja) * 1997-10-20 2001-10-30 アヴァント イムノセラピューティクス,インコーポレーテッド コレステリルエステル運搬タンパク質(cetp)活性を調節するための異種cetp
US6300308B1 (en) * 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
ATE370971T1 (de) * 1999-12-13 2007-09-15 Univ Mexico Nacional Autonoma Quantitative immunoenzymatische messmethode
MX347400B (es) * 2012-06-29 2017-04-18 Univ Nac Autónoma De México Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
CN105859837B (zh) 2014-10-22 2020-11-20 台北医学大学 胆固醇酯转运蛋白抗原肽和融合蛋白以及其组合物和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143305A (en) 1973-05-07 2000-11-07 The Ohio State University Antigenically modified polypeptides composition
US5126399A (en) 1986-04-30 1992-06-30 Board Of Regents, The University Of Texas System Methods and compositions for the preparation and use of site-directed immunologic reagents
US5338829A (en) 1988-04-20 1994-08-16 Trustees Of The University Of Pennsylvania Peptides derived from human immunodeficiency virus-1 GP160
GB8812214D0 (en) 1988-05-24 1988-06-29 Hoffmann La Roche Use of peptide from circumsporozoite protein of p falciparum as universally recognized t-cell epitope
US5242687A (en) 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5264341A (en) * 1989-08-30 1993-11-23 Eli Lilly And Company Selective cloning for high monoclonal antibody secreting hybridomas
JP3183665B2 (ja) 1990-12-10 2001-07-09 エントルメド インコーポレーテッド コレステロール過剰血症およびアテローム性動脈硬化を防止するためのコレステロールに体するワクチン
WO1993011782A1 (en) * 1991-12-19 1993-06-24 Southwest Foundation For Biomedical Research Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
WO1993023076A1 (en) 1992-05-20 1993-11-25 The Johns-Hopkins University Alternative receptor therapy
US5279540A (en) 1992-09-24 1994-01-18 Davidson Michael H Method for reducing the risk of atherosclerosis
US5618683A (en) 1993-04-13 1997-04-08 Brocia; Robert W. Diagnostic kit for cholesteryl ester transfer protein (CETP) activity measurement and a new synthetic particle used therein
JP3795914B2 (ja) 1993-04-27 2006-07-12 ユナイテッド・バイオメディカル・インコーポレイテッド ワクチン用免疫原性lhrhペプチド構築体および合成普遍免疫刺激器
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
AU683295B2 (en) * 1993-08-04 1997-11-06 Texas Biomedical Research Institute CETP inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments
DK96493D0 (da) 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
JPH09501186A (ja) 1994-11-12 1997-02-04 株式会社エルジ化学 コレステリルエステル運搬蛋白質阻害ペプチドおよびこれを含む動脈硬化症のための予防および治療剤
US5705388A (en) 1994-12-23 1998-01-06 Ribozyme Pharmaceuticals, Inc. CETP Ribozymes
US6410022B1 (en) 1995-05-01 2002-06-25 Avant Immunotherapeutics, Inc. Modulation of cholesteryl ester transfer protein (CETP) activity
CA2223177A1 (en) 1995-06-06 1996-12-12 The Immune Response Corporation Method for increasing hdl cholesterol level
WO1997041227A1 (en) 1996-05-01 1997-11-06 T Cell Sciences, Inc. Plasmid-based vaccine for treating atherosclerosis
US6284533B1 (en) 1996-05-01 2001-09-04 Avant Immunotherapeutics, Inc. Plasmid-based vaccine for treating atherosclerosis
US5994310A (en) 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII

Also Published As

Publication number Publication date
US7074407B1 (en) 2006-07-11
AU6091296A (en) 1996-12-24
JPH11507910A (ja) 1999-07-13
DK0831881T3 (da) 2003-07-07
DE69626642T2 (de) 2004-01-29
AU715410B2 (en) 2000-02-03
EP0831881B1 (de) 2003-03-12
CA2223177A1 (en) 1996-12-12
ES2190470T3 (es) 2003-08-01
JP3910635B2 (ja) 2007-04-25
ATE234109T1 (de) 2003-03-15
WO1996039168A1 (en) 1996-12-12
EP0831881A1 (de) 1998-04-01

Similar Documents

Publication Publication Date Title
NZ314058A (en) Use of ganglioside-KLH conjugate vaccines with QS-21 to treat cancer
IL111134A0 (en) Immunological tolerance-inducing agent
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
MXPA02005576A (es) Vacuna para la prevencion y tratamiento de la enfermedad de alzheimer y otras enfermedades relacionadas con amiloides.
TR199801722T2 (xx) Peptit imm�nojenler.
EA199700272A1 (ru) Вакцины, содержащие сапонин и стерин
DE69738138D1 (de) Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
EP0090581A3 (de) Kleine, für Maul- und Klauenseuche spezifische Peptide
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
DE69626642T2 (de) Cetp zur erhöhung des hdl-cholesterol-gehalts
DE69333448D1 (en) P53 impfstoff
HK1005541A1 (en) Treatment of helicobacter associated gastroduodenal disease
BR0312808A (pt) Proteìna de fusão igg fc/hiv-gp120/c3d
AU7237391A (en) Carrier-bound recombinant protein, process for producing it and its use as an immunogen and vaccine
WO2003000719A3 (en) Multiple antigenic peptide displaying multiple copies of an epitope of plaque-forming polypeptide and methods of using same
HUT69920A (en) Evh-4 glycoprotein vaccine
WO1999065518A3 (en) Lt and ct in parenteral immunization methods against helicobacter infection
FI932759A0 (fi) Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
AU6461594A (en) Induction of protection against viral infection
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
WO2000018429A3 (en) Vaccine based on attenuated $i(haemophilus somnus)
MX9707295A (es) Metodo para mejorar la respuesta de los anticuerpos a los antigenos especificos con interleucina-10.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee